

Ingolf Cascorbi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3440596/ingolf-cascorbi-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 papers	11,149 citations	56 h-index	97 g-index
260 ext. papers	12,153 ext. citations	4.8 avg, IF	6.11 L-index

#	Paper	IF	Citations
228	Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 3473-8	11.5	1017
227	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 169-74	6.1	541
226	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs 2006 , 112, 457-73		274
225	Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 535-41		270
224	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. <i>Gastroenterology</i> , 2003 , 124, 26-33	13.3	266
223	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 584-94	6.1	243
222	Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. <i>Molecular Psychiatry</i> , 2005 , 10, 220-4	15.1	232
221	MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. <i>Brain Pathology</i> , 2007 , 17, 347-53	6	189
220	Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 303-12	2.8	186
219	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 572-83	6.1	161
218	Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1733-8	5.9	157
217	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 326-32	6.1	156
216	CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. <i>Carcinogenesis</i> , 2003 , 24, 875-82	4.6	152
215	Functional gene variants of CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 340-8	6.1	146
214	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
213	Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. <i>Pharmacogenomics Journal</i> , 2007 , 7, 56-65	3.5	136
212	P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. <i>Handbook of Experimental Pharmacology</i> , 2011 , 261-83	3.2	135

211	Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 192-200	6.1	134
210	CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokersDung: comparison with aromatic/hydrophobic adduct formation. <i>Carcinogenesis</i> , 2002 , 23, 1969-77	4.6	133
209	The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. <i>Current Alzheimer Research</i> , 2004 , 1, 121-5	3	131
208	Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 896-904	4	129
207	CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. <i>International Journal of Cancer</i> , 2003 , 104, 650-7	7.5	121
206	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nature Communications</i> , 2014 , 5, 4757	17.4	118
205	MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 610-6	3.8	114
204	Modulation of benzo[a]pyrene diol-epoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. <i>Carcinogenesis</i> , 2000 , 21, 35-41	4.6	113
203	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 81, 228-34	6.1	105
202	CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 213-22	6.1	102
201	Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. <i>PLoS ONE</i> , 2011 , 6, e17387	3.7	102
200	Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. <i>International Journal of Epidemiology</i> , 2003 , 32, 60-3	7.8	98
199	Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 458-63	4.6	98
198	Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. <i>Carcinogenesis</i> , 2001 , 22, 453-9	4.6	93
197	Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1337-54	5.5	89
196	Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). <i>Biochemical Pharmacology</i> , 1999 , 58, 1759-64	6	89
195	Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. <i>Journal of Histochemistry and Cytochemistry</i> , 2002 , 50, 1351-6	3.4	87
194	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). <i>Cancer Causes and Control</i> , 2003 , 14, 339-46	2.8	83

193	Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. <i>Pharmacogenomics Journal</i> , 2005 , 5, 365-73	3.5	82
192	Drug interactions--principles, examples and clinical consequences. <i>Deutsches A&#x0308;rzteblatt International</i> , 2012 , 109, 546-55; quiz 556	2.5	81
191	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 206-17	6.1	81
190	Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. <i>American Journal of Pathology</i> , 2003 , 163, 1567-77	5.8	81
189	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 353-62	1.9	79
188	The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. <i>Journal of Histochemistry and Cytochemistry</i> , 2006 , 54, 215-21	3.4	77
187	A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. <i>Lancet, The</i> , 1999 , 353, 708-12	4.0	77
186	Arylamine N-acetyltransferase activity in man. <i>Drug Metabolism Reviews</i> , 1999 , 31, 489-502	7	75
185	Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3' flanking region. <i>The Clinical Investigator</i> , 1994 , 72, 240-8		74
184	Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 357-65	1.9	73
183	Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 381-5		71
182	MicroRNAs and their relevance to ABC transporters. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 587-96	3.8	70
181	Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. <i>Molecular Pharmacology</i> , 2011 , 80, 314-20	4.3	66
180	Genetic basis of toxic reactions to drugs and chemicals. <i>Toxicology Letters</i> , 2006 , 162, 16-28	4.4	66
179	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. <i>PLoS ONE</i> , 2016 , 11, e0162866	3.7	66
178	Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. <i>Pharmacogenomics Journal</i> , 2011 , 11, 25-34	3.5	62
177	MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 198-205	1.9	62
176	A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 830, 143-50	3.2	60

175	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019 , 156, 1707-1716.e2	13.3	59
174	Molecular genetics of cancer susceptibility. <i>Pharmacology</i> , 2000 , 61, 212-27	2.3	57
173	Pitfalls in N-acetyltransferase 2 genotyping. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 123-7		57
172	miRNAs as mediators of drug resistance. <i>Epigenomics</i> , 2012 , 4, 369-81	4.4	56
171	High DNA damage by benzo[a]pyrene 7,8-diol-9,10-epoxide in bronchial epithelial cells from patients with lung cancer: comparison with lung parenchyma. <i>Cancer Letters</i> , 2004 , 207, 157-63	9.9	56
170	Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. <i>Archives of General Psychiatry</i> , 2001 , 58, 93-4		55
169	Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. <i>Neuropsychobiology</i> , 2004 , 50, 305-10	4	54
168	High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 133-40		53
167	Hematopoietic stem cell involvement in positive ALL as a potential mechanism of resistance to blinatumomab therapy. <i>Blood</i> , 2017 , 130, 2027-2031	2.2	52
166	Pharmacogenetics of ATP-binding cassette transporters and clinical implications. <i>Methods in Molecular Biology</i> , 2010 , 596, 95-121	1.4	52
165	Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. <i>Pharmacogenomics Journal</i> , 2007 , 7, 325-32	3.5	52
164	HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 218-24	1.9	50
163	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 519-30		49
162	Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 135-41		46
161	Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014 , 20, 985-94	12.9	45
160	Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 613-7	1.7	45
159	Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. <i>Veterinary Research</i> , 2011 , 42, 98	3.8	44
158	Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005 , 592, 45-57	3.3	43

157	Polymorphisms in xenobiotic conjugation and disease predisposition. <i>Toxicology Letters</i> , 1998 , 102-103, 173-83	4.4	43
156	Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 755-61		43
155	Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis. <i>Genetics in Medicine</i> , 2007 , 9, 67-73	8.1	42
154	Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 256-64	6.1	42
153	Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. <i>Atherosclerosis</i> , 2001 , 154, 651-8	3.1	41
152	Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 624-30	1.9	40
151	Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1947-56	4.5	40
150	Myeloperoxidase--463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. <i>Carcinogenesis</i> , 2001 , 22, 1015-8	4.6	40
149	Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 103??112		40
148	Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. <i>Pharmacogenomics</i> , 2009 , 10, 1941-53	2.6	39
147	Elimination half-life of anti-Müllerian hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2160-3	5.6	37
146	Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 761-4	3.8	37
145	Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. <i>Scandinavian Journal of Work, Environment and Health</i> , 1996 , 22, 332-8	4.3	37
144	Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 288-95	3.2	36
143	Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. <i>BMC Cancer</i> , 2013 , 13, 617	4.8	35
142	Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. <i>Genes and Immunity</i> , 2002 , 3, 102-6	4.4	35
141	Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 376-82	6.1	35
140	The Nomenclature, Definition and Distinction of Types of Shock. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 757-768	2.5	35

139	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. <i>Pharmacogenomics</i> , 2013 , 14, 485-94	2.6	34
138	High frequency of CYP1A1 mutations in a Turkish population. <i>Archives of Toxicology</i> , 1998 , 72, 215-8	5.8	34
137	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 440-50	3.8	34
136	Functional significance of a hereditary adenine insertion variant in the 5'UTR of the endothelin-1 gene. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 445-51		34
135	SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients. <i>Neurobiology of Disease</i> , 2015 , 77, 127-40	7.5	33
134	Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. <i>Epilepsia</i> , 2008 , 49, 1555-61	6.4	33
133	Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. <i>Pharmacopsychiatry</i> , 2000 , 33, 218-20	2	33
132	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , 2019 , 20, 643-657	2.6	31
131	Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 416-22	6.1	30
130	Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. <i>Journal of Hypertension</i> , 2005 , 23, 1361-6	1.9	30
129	Endothelial NO synthase polymorphisms and postural tachycardia syndrome. <i>Hypertension</i> , 2005 , 46, 1103-10	8.5	30
128	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 317-325	6.1	30
127	Paraoxonase 1 mutations in a Turkish population. <i>Toxicology and Applied Pharmacology</i> , 1999 , 157, 174-74.6		29
126	ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics?. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 87, 15-8	6.1	28
125	Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 43-6	6.1	28
124	Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?. <i>Pharmacopsychiatry</i> , 1999 , 32, 110-2	2	28
123	NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 257-9		28
122	Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 283-91	1.9	27

121	Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 327-31		27
120	Pharmacogenetics-based new therapeutic concepts. <i>Drug Metabolism Reviews</i> , 2004 , 36, 617-38	7	27
119	Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system. <i>Xenobiotica</i> , 2001 , 31, 345-56	2	27
118	How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000 , 38, 869-76	5.9	27
117	Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1023-7	5.1	27
116	Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 535-45		27
115	Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation. <i>Journal of Biological Chemistry</i> , 2012 , 287, 27087-94	5.4	26
114	Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 559-63		26
113	The Neurophysiology and Treatment of Motion Sickness. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 687-696	2.5	26
112	Interaction of herbal products with prescribed medications: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2019 , 141, 397-408	10.2	25
111	OpenVigil--free eyeballs on AERS pharmacovigilance data. <i>Nature Biotechnology</i> , 2012 , 30, 137-8	44.5	25
110	CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 303-7		25
109	Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine. <i>Molecular Pharmaceutics</i> , 2017 , 14, 2245-2253	5.6	24
108	Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 389-95	2.8	23
107	N-Acetyltransferase 2 (NAT2) and Glutathione S-Transferase μ (GSTM1) in Bladder-cancer Patients in a Highly Industrialized Area. <i>International Journal of Occupational and Environmental Health</i> , 1997 , 3, 105-110		23
106	Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 1035-1046	3.9	23
105	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. <i>Oncology Research and Treatment</i> , 2020 , 43, 628-636	2.8	22
104	Endothelial nitric oxide synthase Glu(298)-->Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. <i>Clinical Science</i> , 2005 , 109, 475-81	6.5	21

103	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. <i>Pharmacological Research</i> , 2020 , 161, 105250	10.2	21
102	Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions. <i>Frontiers in Pharmacology</i> , 2016 , 7, 396	5.6	21
101	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004 , 110, 266-70	7.5	20
100	Interaction of xenobiotics on the glucose-transport system and the Na ⁺ /K ⁺ -ATPase of human skin fibroblasts. <i>Ecotoxicology and Environmental Safety</i> , 1991 , 21, 38-46	7	20
99	Comparison of extremes Approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. <i>Cancer Letters</i> , 2005 , 221, 177-83	9.9	19
98	Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the beta3-adrenergic receptor. <i>International Journal of Obesity</i> , 2000 , 24, 369-75	5.5	19
97	Correlation between the lipophilicity of substituted phenols and their inhibition of the Na ⁺ /K ⁺ -ATPase of Chinese hamster ovary cells. <i>Toxicology</i> , 1989 , 58, 197-210	4.4	18
96	Drug Hypersensitivity. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 501-512	2.5	18
95	Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 207-14	3.5	17
94	Length variants of the ABCB1 3'UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance. <i>Pharmacogenomics</i> , 2016 , 17, 327-40	2.6	17
93	Pharmacogenomics of heart failure -- focus on drug disposition and action. <i>Cardiovascular Research</i> , 2004 , 64, 32-9	9.9	17
92	Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1520-5	15.1	17
91	Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. <i>Pharmacogenomics</i> , 2016 , 17, 367-74	2.6	16
90	Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010 , 107, 570-6	3.1	16
89	Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. <i>European Journal of Clinical Pharmacology</i> , 2004 , 60, 17-21	2.8	16
88	Association between the N-acetylation genetic polymorphism and bronchial asthma. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 671-4	3.8	16
87	Effects of a heterogeneous set of xenobiotics on growth and plasma membranes of mammalian and fungal cell cultures. <i>Ecotoxicology and Environmental Safety</i> , 1993 , 26, 113-26	7	16
86	Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 478-80	6.1	16

85	Implementation and obstacles of pharmacogenetics in clinical practice: An international survey. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2076-2088	3.8	14
84	Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine. <i>Molecular Pharmaceutics</i> , 2019 , 16, 3823-3830	5.6	14
83	Expression of N-acetyltransferases in periodontal granulation tissue. <i>Journal of Dental Research</i> , 2002 , 81, 349-53	8.1	14
82	MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. <i>Oncotarget</i> , 2017 , 8, 92018-92031	3.3	14
81	The beta3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2001 , 50, 184-8	12.7	13
80	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. <i>Scientific Reports</i> , 2019 , 9, 7323	4.9	12
79	miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 1585-1594	5.7	12
78	Peptide nucleic acid-mediated polymerase chain reaction clamping allows allelic allocation of CYP1A1 mutations. <i>Analytical Biochemistry</i> , 1997 , 250, 256-7	3.1	12
77	A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. <i>European Journal of Clinical Investigation</i> , 2007 , 37, 558-65	4.6	12
76	No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. <i>Neurology</i> , 2006 , 66, 1753-5	6.5	12
75	Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 435-40	1.7	12
74	A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. <i>American Heart Journal</i> , 2000 , 140, 170-5	4.9	12
73	Challenges in pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69 Suppl 1, 17-23	2.8	11
72	Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method. <i>Chemico-Biological Interactions</i> , 2011 , 191, 104-125		11
71	Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. <i>Pharmacogenomics</i> , 2011 , 12, 1051-9	2.6	11
70	Co-trimoxazole-induced liver and renal failure. Case report. <i>European Journal of Clinical Pharmacology</i> , 2000 , 56, 191-3	2.8	11
69	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 369-396	5.5	11
68	Alternative Polyadenylation of ABC Transporters of the C-Family (ABCC1, ABCC2, ABCC3) and Implications on Posttranscriptional Micro-RNA Regulation. <i>Molecular Pharmacology</i> , 2020 , 97, 112-122	4.3	10

67	Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. <i>Pharmacopsychiatry</i> , 2008 , 41, 258-9	2	10
66	Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 77-83	1.9	10
65	Influence of an insertion variant in the 5'UTR of the endothelin-1 gene on orthostatic intolerance. <i>American Journal of the Medical Sciences</i> , 2005 , 330, 166-71	2.2	10
64	Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 875-81	1.9	10
63	Short Report: TRPV1-polymorphism 1911 A>G alters capsaicin-induced sensory changes in healthy subjects. <i>PLoS ONE</i> , 2017 , 12, e0183322	3.7	10
62	Neurodegenerative effects of azithromycin in differentiated PC12 cells. <i>European Journal of Pharmacology</i> , 2017 , 809, 1-12	5.3	9
61	Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. <i>European Journal of Clinical Pharmacology</i> , 2003 , 59, 527-31	2.8	9
60	Retinoic acid-induced survival effects in SH-SY5Y neuroblastoma cells. <i>Journal of Cellular Biochemistry</i> , 2019 , 120, 5974-5986	4.7	9
59	MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2. <i>Xenobiotica</i> , 2018 , 48, 1050-1058	2	8
58	Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017 , 390, 949-959	3.4	8
57	Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. <i>Journal of Molecular Medicine</i> , 2003 , 81, 305-9	5.5	8
56	Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 27	7.8	8
55	SIGMA-1 Receptor Gene Variants Affect the Somatosensory Phenotype in Neuropathic Pain Patients. <i>Journal of Pain</i> , 2019 , 20, 201-214	5.2	8
54	Advances and challenges in hereditary cancer pharmacogenetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 73-82	5.5	7
53	Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor β -independent mechanism. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017 , 390, 37-48	3.4	7
52	Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. <i>Clinical Chemistry</i> , 2004 , 50, 448-51	5.5	7
51	Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPAR α dependent mechanism. <i>Neoplasma</i> , 2017 , 64, 395-405	3.3	6
50	Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 718-25	4	6

49	A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2013 , 31, 661-8	4.3	6
48	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. <i>Blood</i> , 2000 , 96, 2002-2003	2.2	6
47	Hyperhomocysteinaemia and adverse events complicating coronary catheter interventions. <i>International Journal of Cardiology</i> , 2000 , 76, 211-7	3.2	6
46	Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. <i>Frontiers in Pharmacology</i> , 2021 , 12, 696960	5.6	6
45	Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. <i>Intensivmedizin Und Notfallmedizin</i> , 2005 , 42, 531-543		5
44	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 180-182 ⁷		5
43	The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients. <i>European Journal of Pain</i> , 2021 , 25, 595-611	3.7	5
42	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. <i>Journal of Community Genetics</i> , 2019 , 10, 523-530	2.5	4
41	Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. <i>Liver International</i> , 2006 , 26, 285-90	7.9	4
40	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4421-4431 ⁴	3.8	4
39	Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes. <i>Deutsches A&#x0308;rztblatt International</i> , 2021 , 118,	2.5	4
38	Plan S: A threat to quality of science?. <i>Science</i> , 2019 , 363, 462	33.3	3
37	Targeting gene expression during the early bone healing period in the mandible: A base for bone tissue engineering. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2015 , 43, 1452-60	3.6	3
36	Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. <i>Clinical Therapeutics</i> , 2010 , 32, 347-56	3.5	3
35	The Pharmacogenetics of Immune-Modulating Therapy. <i>Advances in Pharmacology</i> , 2018 , 83, 275-296	5.7	2
34	Pharmacogenomics in acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 363-76	4	2
33	Effects of a heterogeneous set of xenobiotics on RNA synthesis of yeast cells. <i>Ecotoxicology and Environmental Safety</i> , 1995 , 30, 252-8	7	2
32	Influence of doxorubicin on gene expression and protein pattern in HeLa cells. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004 , 42, 640-1	2	2

31	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2005 , 93, 180-2	7	2
30	Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells. <i>Molecular and Cellular Neurosciences</i> , 2017 , 82, 12-22	4.8	1
29	Pharmakogenetik. <i>Medizinische Genetik</i> , 2017 , 29, 389-396	0.5	1
28	4th ESPT Conference: pharmacogenomics and personalized medicine research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019 , 20, 1063-1069	2.6	1
27	P-glycoprotein (MDR1/ABCB1) 2013 , 271-293		1
26	Stellungnahme der Sektion Schock der DIVI zur Schocklage. <i>Notarzt</i> , 2012 , 28, 12-16	0.3	1
25	Kardiopulmonale Reanimation CPR. <i>Intensivmedizin Und Notfallmedizin</i> , 2006 , 43, 446-451		1
24	Pharmakodynamik 2011 , 15-43		1
23	Drug-Drug-Gene Interactions: A Call for Clinical Consideration. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 549-551	6.1	1
22	ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2021 , 99, 54-64.e7	3.1	1
21	Safe and effective medicines for all: is personalized medicine the answer?. <i>Expert Review of Clinical Pharmacology</i> , 2010 , 3, 627-37	3.8	0
20	Limited Impact of 6-Mercaptopurine on Inflammation-Induced Chemokines Expression Profile in Primary Cultures of Enteric Nervous System. <i>Neurochemical Research</i> , 2021 , 46, 1781-1793	4.6	0
19	High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). <i>European Journal of Pain</i> , 2021 , 25, 1739-1750	3.7	0
18	Involvement of medical students in a surgery congress: impact on learning motivation, decision-making for a career in surgery, and educational curriculum. <i>Wiener Medizinische Wochenschrift</i> , 2021 , 171, 182-193	2.9	0
17	TRP Gene Polymorphism and Disease Risk 2015 , 59-87		
16	Pharmacogenetics of Phase II Drug Metabolizing Enzymes 2012 , 81-100		
15	Highlights from the latest articles in breast cancer pharmacogenomics. <i>Pharmacogenomics</i> , 2012 , 13, 645-9	2.6	
14	Pharmakogenetik in der Kardiologie. <i>Kardiologie</i> , 2007 , 1, 272-280	0.6	

13	OV-A-2. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, P34-P34	6.1
12	Pharmacogenomics of Bioavailability and Elimination. <i>Methods and Principles in Medicinal Chemistry</i> , 2003 , 363-380	0.4
11	The G protein subunit beta3 and early complications after coronary catheter interventions. <i>Atherosclerosis</i> , 2000 , 153, 523-4	3.1
10	Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3. <i>Biomarkers</i> , 1999 , 4, 129-34	2.6
9	Neonatale Pharmakologie 2005 , 643-659	
8	The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. <i>Blood</i> , 2000 , 96, 2002-2003	2.2
7	Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2002 , 40, 562-3	2
6	CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH). <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2004 , 42, 78-82	2
5	Replication of Genetic Markers Associated with Clozapine-Induced Agranulocytosis.. <i>Blood</i> , 2006 , 108, 1280-1280	2.2
4	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2018 , 115, 713	2.5
3	Germline variants in cancer therapy. 2019 , 2, 18-30	
2	Correspondence (reply): In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 133	2.5
1	Interaction of Phytocompounds of with ABCB1 and ABCG2 Efflux Transporters. <i>Molecular Pharmaceutics</i> , 2021 , 18, 1622-1633	5.6